Kyprolis is given by a doctor or nurse and billed by the clinic, not a pharmacy. Your care team and your insurance decide which product you get, so ask them what you’d pay.

How do you pay?

How to pay the least

Given by your care team

Billed by the clinic

Kyprolis is given by a doctor or nurse, not picked up at a pharmacy.

  1. Ask your care team or your plan what you’d pay before your visit.

Compare every option

Question
Brand nameKyprolis
Authorized genericcarfilzomib
Regular genericcarfilzomib
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNone found
Same as Kyprolis?
The original
–
–

Brand nameThe maker’s card

Amgen SupportPlus Co-Pay Program

Savings card from Amgen

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a dose

Sign up on kyprolis.com 

Or call 1-866-264-2778.

In the maker’s words

“Pay as little as $0 out-of-pocket for each dose…”

From the maker’s offer on kyprolis.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Authorized genericNot sold

There isn’t one. An authorized generic is Kyprolis itself, from the same company, sold without the brand name, and usually for less. For now Kyprolis is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

Kyprolis is a proteasome inhibitor that is indicated:

  • for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with
    • Lenalidomide and dexamethasone; or
    • Dexamethasone; or
    • Daratumumab and dexamethasone; or
    • Daratumumab and hyaluronidase-fihj and dexamethasone; or
    • Isatuximab and dexamethasone.
  • as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.

Source: the FDA label for Kyprolis (Onyx Pharmaceuticals, Inc.), June 18, 2025. Full label on DailyMed 

Good to know